About this trial
Ketamine is a medication that came into clinical practice in the 1960's. Ketamine is used as an anesthetic and to provide pain relief. Recently, Ketamine was approved to treat drug resistant depression using subanesthetic doses. In the hospital setting, intravenous anesthetic dosages are used to treat unrelenting seizures known as status epilepticus in comatose patients. Ketamine in subanesthetic doses has not been tried as a treatment for medication resistant seizures in the outpatient setting. This study would like to examine the effectiveness of subanesthetic ketamine in outpatients who suffer from drug resistant epilepsy.
Eligibility criteria
Qualifiers
Provision of signed and dated informed consent form
Adults (18 years or older)
Cognitively impaired adults are not excluded (i.e. will be included in the study)
Established diagnosis of Drug Resistant Epilepsy (DRE) i.e. failed two or more appropriately chosen anti-seizure medications (ASMs)
Disqualifiers
Patients <18 years of age
Pregnant women
Women that are breast feeding
Patients who had >21 days of seizure freedom in the last year.
Trial design
Treatments tested in this trial
- Ketamine Hydrochloride
Treatment groups
Sponsors and collaborators
Madeline Fields
Lead sponsor
Icahn School of Medicine at Mount Sinai
Sponsor institution